+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd Key Recent Developments

  • Aug 28, 2024: Shionogi to Announce Personnel Reassignment
  • Jul 29, 2024: Shionogi & Co : Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS)
  • Jul 11, 2024: Shionogi : Notice of Head Office Relocation
  • Jul 08, 2024: Domestic Launch of the In Vitro Diagnostic Pharmaceutical "Shionogi MIC Dry Plate Cefiderocol"

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Shionogi & Co Ltd - Key Facts
  • Shionogi & Co Ltd - Key Employees
  • Shionogi & Co Ltd - Key Employee Biographies
  • Shionogi & Co Ltd - Major Products and Services
  • Shionogi & Co Ltd - History
  • Shionogi & Co Ltd - Company Statement
  • Shionogi & Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
  • Business Unit
Section 2 - Company Analysis
  • Company Overview
  • Shionogi & Co Ltd - Business Description
  • R&D Overview
  • Shionogi & Co Ltd - Corporate Strategy
  • Shionogi & Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Shionogi & Co Ltd - Strengths
  • Shionogi & Co Ltd - Weaknesses
  • Shionogi & Co Ltd - Opportunities
  • Shionogi & Co Ltd - Threats
  • Shionogi & Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Shionogi & Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 28, 2024: Shionogi to Announce Personnel Reassignment
  • Jul 29, 2024: Shionogi & Co : Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS)
  • Jul 11, 2024: Shionogi : Notice of Head Office Relocation
  • Jul 08, 2024: Domestic Launch of the In Vitro Diagnostic Pharmaceutical "Shionogi MIC Dry Plate Cefiderocol"
  • Jul 01, 2024: Laboratory of International Wastewater-based Epidemiology Established at the school of Engineering, the University of Tokyo
  • Jun 03, 2024: Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
  • May 31, 2024: Position and Policy Regarding Reduction of the Investment Unit
  • May 30, 2024: Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections
  • May 13, 2024: Shionogi & Co : Consolidated Financial Results for Fiscal Year 2023 (IFRS)
  • Mar 04, 2024: Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Shionogi & Co Ltd, Key Facts
  • Shionogi & Co Ltd, Key Employees
  • Shionogi & Co Ltd, Key Employee Biographies
  • Shionogi & Co Ltd, Major Products and Services
  • Shionogi & Co Ltd, History
  • Shionogi & Co Ltd, Subsidiaries
  • Shionogi & Co Ltd, Joint Venture
  • Shionogi & Co Ltd, Business Unit
  • Shionogi & Co Ltd, Key Competitors
  • Shionogi & Co Ltd, Ratios based on current share price
  • Shionogi & Co Ltd, Annual Ratios
  • Shionogi & Co Ltd, Interim Ratios
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Shionogi & Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Shionogi & Co Ltd, Performance Chart (2020 - 2024)
  • Shionogi & Co Ltd, Ratio Charts
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Wakamoto Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Santen Pharmaceutical Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Otsuka Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd